Dual staining for p16/Ki67 is a more specific test than cytology for triage of HPV-positive women
- 105 Downloads
Globally, cervical cancer (CC) screening is moving from cytology-based to HPV screening or a combination of both (co-testing). Most HPV-positive women clear the virus and do not develop relevant disease. Additional triage approaches are needed to reduce unnecessary colposcopy referrals. The p16/Ki67 dual stain cytology test (DSCT) is one of the most promising, but it has not (yet) been included as a recommendation in European guidelines. Previous studies in Spain on this issue are lacking. We studied the performance of p16/Ki67 DSCT for the triage of HPV-positive women in Navarra to detect precursor lesions (PLs) and CC compared to cytology only. We selected 1865 HPV-positive women with p16/Ki67 DSCT results and 304 women with an available biopsy result. Sensitivity, specificity and predictive values of the p16/Ki67 DSCT to detect underlying PLs and CC compared to cytology were calculated, using the biopsy as the gold standard. Cytology and p16/Ki67 DSCT showed similar sensitivity (99.0% vs. 98.0%), but cytology had significantly lower specificity (6.9 vs. 39.1%). Of the CIN2+/HPV+ women, triage using cytology only would have resulted in 40.2% true PLs and CC, while using p16/Ki67 DSCT this was 98.0% qualifying the women for colposcopy referral. Our results show that p16/Ki67 DSCT detects more than twice as many true PLs and CC than cytology only in this population. Thus, this test can be considered as an important additional tool in HPV testing-based screening strategies, to avoid unnecessary colposcopy referrals and to reduce health care costs.
KeywordsCervical cancer Cytology Human papillomavirus (HPV) Screening Dual immunostaining
We are grateful to Elena Almudévar, Rosa Guarch and Oscar Manzanilla for their advisory and for taking the last look at the manuscript. We also thank the technicians of the Pathology Department at “Complejo Hospitalario de Navarra” for their valuable contribution to this study.
Compliance with ethical standards
This manuscript complies with local ethics guidelines.
Conflict of interest
The authors declare that they have no conflicts of interest.
F. Mallor partially supported by MTM2016-77015-R (AEI, FEDER, UE).
I. Paniello partially supported by MTM2017-83506-C2-1-P.
The other authors made no disclosures.
Ethical responsibilities of author section
ACC and SMM designed the study and contributed substantially with the acquisition and interpretation of data. MGM collected the data. PAI and MGF did the data analysis. ACC wrote the manuscript. LEM and CIA contributed substantially with the interpretation of data for the work. All authors contributed revising the work critically for important intellectual content and final approval of the version to be published.
- 4.Wentzensen N, Bergeron C, Cas F, Vinokurova S, von Knebel Doeberitz M. Triage of women with ASCUS and LSIL cytology. Cancer 2006;111(1):58–66. https://doi.org/10.1002/cncr.22420
- 7.Waldstrøm M, Christensen RK, Ornskov D (2013) Evaluation of p16INK4a/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion. Cancer Cytopathol. 121(3):136–145. https://doi.org/10.1002/cncy.21233 CrossRefPubMedGoogle Scholar
- 8.Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold MA, Allen RA, Zhang R, Dunn ST, Walker JL, Schiffman M (2012) Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res 18(15):4154–4162. https://doi.org/10.1158/1078-0432.CCR-12-0270 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Bergeron C, Ronco G, Reuschenbach M, Wentzensen N, Arbyn M, Stoler M, von Knebel Doeberitz M (2015) The clinical impact of using p16INK4a immunochemistry in cervical histopathology and cytology: an update of recent developments. Int J Cancer 136(12):2741–2751. https://doi.org/10.1002/ijc.28900 CrossRefPubMedGoogle Scholar
- 10.Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA (2009) HPV screening for cervical cancer in rural India. N Engl J Med 360(14):1385–1394. https://doi.org/10.1056/NEJMoa0808516 CrossRefPubMedGoogle Scholar
- 12.Ovestad IT, Dalen I, Hansen E, Loge JLD, Dybdahl BM, Dirdal MB, Moltu P, Berland JM (2017) Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program. Cancer Cytopathol. 125(4):283–291. https://doi.org/10.1002/cncy.21807 CrossRefPubMedGoogle Scholar
- 16.Luttmer R, Dijkstra MG, Snijders PJF, Berkhof J, van Kemenade FJ, Rozendaal L, Helmerhorst TJM, Verheijen RHM, ter Harmsel WA, van Baal WM, Graziosi PGCM, Quint WGV, Spruijt JWM, van Dijken DKE, Heideman DAM, Meijer CJLM (2016) p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Mod Pathol 29(8):870–878. https://doi.org/10.1038/modpathol.2016.80 CrossRefPubMedGoogle Scholar
- 17.Benevolo M, Allia E, Gustinucci D, Rollo F, Bulletti S, Cesarini E, Passamonti B, Giovagnoli MR, Carico E, Carozzi FM, Mongia A, Fantacci G, Confortini M, Rubino T, Fodero C, Prandi S, Marchi N, Farruggio A, Coccia A, Macrì L, Ghiringhello B, Ronco G, Bragantini E, Polla E, Maccallini V, Negri G, Giorgi Rossi P, for the New Technologies for Cervical Cancer Screening 2 (NTCC2) Working Group (2017) Interobserver reproducibility of cytologic p16INK4a/Ki-67 dual immunostaining in human papillomavirus-positive women. Cancer Cytopathol. 125(3):212–220. https://doi.org/10.1002/cncy.21800 CrossRefPubMedGoogle Scholar
- 22.Guo M, Khanna A, Wang J, Dawlett MA, Kologinczak TL, Lyons GR, Bassett RL Jr, Sneige N, Gong Y, Bevers TB (2017) Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening. Cancer Cytopathol. 125(8):644–651. https://doi.org/10.1002/cncy.21877 CrossRefPubMedGoogle Scholar
- 23.Ascunce N, Barcos A, Ederra M, Erdozain NRR (2008) Citologías ginecológicas en Navarra 2001–2007. Inst Salud Pública-Sección Detección Precoz:1–89Google Scholar
- 24.Tao X, Austin RM, Zhang H, Zhang L, Xiao J, Zhou X, Wang L, Zhao C (2017) Histopathologic follow-up and HPV test results with HSIL Papanicolaou test results in China’s largest academic women’s hospital. Cancer Cytopathol. 125(12):947–953. https://doi.org/10.1002/cncy.21914 CrossRefPubMedGoogle Scholar
- 26.Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, Bogers J, Dachez R, Denton K, Hariri J, Keller T, von Knebel Doeberitz M, Neumann HH, Puig-Tintore LM, Sideri M, Rehm S, Ridder R, for the PALMS Study Group (2013) Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 105(20):1550–1557. https://doi.org/10.1093/jnci/djt235 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ, Rijkaart D, Berkhof J, Balfoort-van der Meij GAMA, Ridder R, Snijders PJF, Meijer CJLM (2015) Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. Int J Cancer 136(10):2361–2368. https://doi.org/10.1002/ijc.29290 CrossRefPubMedGoogle Scholar
- 29.Uijterwaal MH, Witte BI, Van Kemenade FJ et al (2014) Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study. Br J Cancer 110(6):1579–1586. https://doi.org/10.1038/bjc.2014.34 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Lüthge A, Bergeron C, Kommoss F, Löning T, Ordi J, Regauer S, Ridder R Gynecologic Oncology Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 2011;121(3):505–509. https://doi.org/10.1016/j.ygyno.2011.02.033
- 33.Bergeron C, Ikenberg H, Sideri M, Denton K, Bogers J, Schmidt D, Alameda F, Keller T, Rehm S, Ridder R, for the PALMS Study Group (2015) Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol. 123(6):373–381. https://doi.org/10.1002/cncy.21542 CrossRefPubMedGoogle Scholar
- 34.Loghavi S, Walts AE, Bose S (2013) CINtec® PLUS dual immunostain: a triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion. Diagn Cytopathol 41(7):582–587. https://doi.org/10.1002/dc.22900 CrossRefPubMedGoogle Scholar
- 36.White C, Bakhiet S, Bates M, Keegan H, Pilkington L, Ruttle C, Sharp L, O’ Toole S, Fitzpatrick M, Flannelly G, O’ Leary JJ, Martin CM (2016) Triage of LSIL/ASC-US with p16/Ki-67 dual staining and human papillomavirus testing: a 2-year prospective study. Cytopathology 27(4):269–276. https://doi.org/10.1111/cyt.12317 CrossRefPubMedGoogle Scholar
- 37.Carozzi F, Gillio-Tos A, Confortini M, del Mistro A, Sani C, de Marco L, Girlando S, Rosso S, Naldoni C, Dalla Palma P, Zorzi M, Giorgi-Rossi P, Segnan N, Cuzick J, Ronco G, NTCC working group (2013) Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 14(2):168–176. https://doi.org/10.1016/S1470-2045(12)70529-6 CrossRefPubMedGoogle Scholar
- 38.Iftner T, Becker S, Neis KJ, Castanon A, Iftner A, Holz B, Staebler A, Henes M, Rall K, Haedicke J, von Weyhern CH, Clad A, Brucker S, Sasieni P (2015) Head-to-head comparison of the RNA-based aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany. J Clin Microbiol 53(8):2509–2516. https://doi.org/10.1128/JCM.01013-15 CrossRefPubMedPubMedCentralGoogle Scholar